Viral Vector And Plasmid DNA Testing Services Market, By Service Type (Safety, Genetic Characterization, Purity, Identity and Potency), By End User (Pharmaceutical and Biotechnology Industries and Research Organizations), and By Region (North America, Lat

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	145 Pages	Coherent Market Insights	March, 2025	CMI20007639

Best Price Guarantee
Price	from $4,500
Length	145 Pages
Publisher	Coherent Market Insights
Published Date	March, 2025
SKU	CMI20007639

Testing services are crucial for the timely development of viral vector-based medicines since viral vectors are the best strategy for gene therapies. Characterization of the viral vector plays an essential role for orthogonal analytical methods. Through the regulatory prospective which includes product safety, identification, purity, and potency, the characterization is significant. These days, viral vectors are the primary delivery system for a variety of virus-based medications that have been created for various therapies for conditions including cancer, neurology, hematology, ophthalmology, metabolic or muscular disorders and are accepted on the global market. The pharmaceutical industry has a bright future for several developments based on viral-based medicines.

Market Dynamics

The ongoing clinical trials on the viral vectors and plasmid DNA for various treatment is expected to fuel growth of the market in the forecast period. For instance, in October, 2022, ICON plc, a clinical research organization, in collaboration with researchers from Imam Abdulrahman Bin Faisal University, based in Saudi Arabia, announced the initiation of Phase-I clinical trial Study to Evaluate the Safety and Immunogenicity of 2 or 3 dose regimen of investigational Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults. The pDNA vaccine candidate is administered intramuscularly (IM) by immunizing healthy adults (18-55 years).

Similarly, in January 2022, GeneOne Life Science, Inc., a biotechnology company, in collaboration with Inovio Pharmaceuticals, a biotechnology company, announced initiation of clinical trial to assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus, which is currently in Phase -1.

Key features of the study:

This report provides in-depth analysis of the global viral vector and plasmid DNA testing services market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global viral vector and plasmid DNA testing services market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Charles River Laboratories, Inc., WuXi AppTec Co., Ltd., Cobra Biologics and Pharmaceutical Services, Merck KgaA, Lonza, Eurofins Scientific, FinVector Vision Therapies, Advanced Bioscience Laboratories, Inc., Takara Bio Inc., ViruSure GmbH, Genezen Laboratories, Akron Biotech., Catalent, Inc, AcuraBio., CATUG Biotechnology., Creative Biogene and Aldevron
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global viral vector and plasmid DNA testing services market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA testing services market

Detailed Segmentation:

Global Viral Vector and Plasmid DNA Testing Services Market, By Service Type:
Safety
Genetic Characterization
Purity
Identity
Potency
Global Viral Vector and Plasmid DNA Testing Services Market By End User:
Pharmaceutical and Biotechnology Industries
Research Organizations
Global Viral Vector and Plasmid DNA Testing Services Market, By Region:
North America
U.S.
Canada
Latin America
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
South Africa
Central Africa
North Africa
Company Profiles
Charles River Laboratories, Inc.
WuXi AppTec Co., Ltd.
Cobra Biologics and Pharmaceutical Services
Merck KgaA
Lonza
Eurofins Scientific
FinVector Vision Therapies
Advanced Bioscience Laboratories, Inc.
Takara Bio Inc.
ViruSure GmbH
Genezen Laboratories
Akron Biotech.
Catalent, Inc
AcuraBio
CATUG Biotechnology.
Creative Biogene.
Aldevron

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Service Type; Market Snapshot, By End User; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Attractiveness Analysis; Market Opportunities; Merger, Acquisition, Collaborations; Funding and Investment; Future Prospective of Viral vector and plasma DNA testing; Regulatory Guideline and Compliances; Key Developments; PEST Analysis; PORTER’s Analysis
4. Global Viral Vector and Plasmid DNA Testing Services Market– COVID-19 Impact Analysis: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global Viral Vector and Plasmid DNA Testing Services Market, By Service Type, 2020–2032, (US$ Million): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021 – 2032; Segment Trends; Safety; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million); Genetic Characterization; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million); Purity; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million); Identity; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million); Potency; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
6. Global Viral Vector and Plasmid DNA Testing Services Market, By End User, 2020 – 2032, (US$ Million): Introduction; Market Share Analysis, 2025 and 2032 (%); Y-o-Y Growth Analysis, 2021 – 2032; Segments Trends; Pharmaceutical and Biotechnology Industries; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million); Research Organizations; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2020–2032, (US$ Million)
7. Global Viral Vector and Plasmid DNA Testing Services Market, By Region, 2020 – 2032, (US$ Million): Introduction; Market Share Analysis, By Region, 2025 and 2032 (%); Y-o-Y Growth Analysis, For Region, 2021–2032; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2020 - 2032, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Million); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2020 - 2032, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Million); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2020 - 2032, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Million); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2020 - 2032, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Million); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2020 - 2032, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2032, (US$ Million); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Service Type, 2020 - 2032, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 – 2032, (US$ Million); North Africa; Central Africa; South Africa
8. Competitive Landscape: Charles River Laboratories, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; WuXi AppTec Co., Ltd.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Cobra Biologics and Pharmaceutical Services; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Merck KgaA; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Lonza; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Eurofins Scientific; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; FinVector Vision Therapies; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Advanced Bioscience Laboratories, Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Takara Bio Inc.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; ViruSure GmbH; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Genezen Laboratories; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Akron Biotech.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Catalent, Inc; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; AcuraBio.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; CATUG Biotechnology.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Creative Biogene.; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; Aldevron; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies
9. Section: Research Methodology; About Us; *Browse 32 market data tables and 36 figures on “Global Viral Vector and Plasmid DNA Testing Services Market”- Global forecast to 2032